ELEVATE-ing clinical trial reporting in CLL

Affiliations

Editorial

Florian Simon et al. Blood. 2025.

. 2025 Sep 11;146(11):1253-1254.

doi: 10.1182/blood.2025029318.

No abstract available

Comment on

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn IW, Kamdar M, Munir T, Walewska R, Hughes M, Fogliatto LM, Herishanu Y, Banerji V, Follows G, Walker P, Ghia P, Janssens A, Byrd JC, Ferrant E, Ferrajoli A, Wierda WG, Wachira CW, Suterwala BT, Miranda P, Munugalavadla V, Wun CC, Woyach JA. Sharman JP, et al. Blood. 2025 Sep 11;146(11):1276-1285. doi: 10.1182/blood.2024024476. Blood. 2025. PMID: 40198878 Clinical Trial.